Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of allo-SCT for R/R CD22+ Lymphoid Malignancies"

27 views
December 17, 2023
Comments 0
Login to view comments. Click here to Login